OBJECTIVE: To determine the effect of an a 2 -adrenoceptor antagonist, idazoxan, on the sympathetic nervous system and on energy expenditure responses after an oral glucose load, in obese patients. (idazoxan acts as an indirect sympathomimetic drug through blockade of presynaptic a 2 -adrenoceptors). DESIGN: Double-blind randomized placebo-controlled cross-over study. Idazoxan (40 mg) or placebo were administered orally 90 min before a 100 g oral glucose load. SUBJECTS: Twelve long-standing obese subjects (six men and six women, age range from 24 to 45 y, body mass index range from 30.2 to 41.3 kgam 2 ). MEASUREMENTS: Energy expenditure was derived from oxygen consumption and carbon dioxide production according to indirect calorimetry. Plasma samples were obtained for plasma adrenaline and noradrenaline, glucose, non-esteri®ed fatty acid (NEFA), glycerol and insulin determinations. RESULTS: The plasma noradrenaline concentration response to the glucose load was signi®cantly higher after idazoxan than after placebo administration. The time-course of glucose load-induced thermogenesis was not signi®cantly different after administration of idazoxan nor placebo. Idazoxan administration did not modify the insulin, non-esteri®ed fatty acids or glycerol concentration responses to the glucose load. Neither heart rate nor blood pressure values were modi®ed by idazoxan when compared to placebo. However, idazoxan signi®cantly improved glucose tolerance. CONCLUSION: The a 2 -adrenergic antagonist idazoxan increases glucose-induced sympathetic activity but not energy expenditure in obese subjects. These data do not argue for the development of a a 2 AR antagonist compounds as antiobesity treatment.
Introduction
Obesity can be treated using several modalities including energy restriction, behavioral modi®cation, exercise and drug therapies. Apart from the anorectic drugs, one pharmacological approach to obtain greater and more prolonged weight loss could be to improve lipid mobilization and energy expenditure (EE) using agents acting on to sympathetic nervous system (SNS).
Two major strategies can be proposed to modulate SNS activity. The ®rst one is to stimulate directly the b-adrenoceptors (AR). This approach is strongly limited by the cardiovascular side effects of b2-AR agonists and the weak ef®cacy of putative b3-AR agonists. The second one is to promote indirectly SNS activation using a 2 -AR antagonists. The stimulation of noradrenaline release is controlled by a negative feedback mechanism involving presynaptic a 2 -AR. The blockade of such receptors with an a 2 -AR antagonist could result in an increase of noradrenaline out¯ow. 1 Acute administration of yohimbine, a regular a 2 -AR antagonist, has been shown to promote the activation of the SNS in obese as well as in normal subjects. 2 ± 4 The thermogenesis induced by food intake involves two components: obligatory thermogenesis which is due to the metabolic cost, absorption and storage of the nutrients, 5 and facultative thermogenesis, which is attributed to an activation of the SNS, especially when food intake is mainly based on carbohydrates. 6 ± 9 Several studies have also suggested that obesity could be associated with a defect in diet-induced thermogenesis. 10 ± 14 This suggests that compounds modulating SNS activity in order to improve the facultative component of diet-induced thermogenesis are potential antiobesity drugs.
In the light of these data, we decided to conduct a double-blind placebo-controlled study in a cross-over design to investigate if acute administration of idazoxan, a selective a 2 -AR antagonist, 15 could increase both SNS activity and EE after an oral glucose load, in obese patients.
Subjects and methods

Subjects
Twelve obese subjects (six men and six women) were included in the study. . Their body weight was stable for at least 3 months before the beginning of the study. All subjects were free from metabolic disorders or thyroid diseases. None of them exhibited arterial hypertension or coronary heart disease. They were not taking drugs, except for two women who were taking oral contraceptives. The investigation protocol was approved by the Ethical Committee of the Toulouse University Hospital. The subjects signed an informed written consent for the protocol.
Experimental protocol
All experiments were performed with the subjects in supine position after a 10 ± 12 h overnight fast, and carried out in a temperature-controlled room (25 C). A catheter was inserted at 8:00 a.m. into an antecubital vein for blood sampling, and kept patent with isotonic saline solution. After a 30 min rest period (T 0 min), continuous respiratory exchanges were measured over 30 min, then the subjects received an oral capsule containing 40 mg idazoxan or an identical placebo. Idazoxan and placebo were administered according to a double-blind randomized cross-over procedure, the second test being performed at least 1 week later. Respiratory exchanges were measured at T 90 to T 120 min (30 min period). Then, at T 120 min, an oral load of 100 g glucose was administered in 300 ml water within a 3 ± 4 min period. Indirect calorimetry measurements were continued throughout until T 300 min (i.e. 180 min after glucose ingestion). Blood samples were obtained at T 30 , T 120 , T 150 , T 180 , T 210 , T 240 , T 270 and T 300 min for plasma glucose, nonesteri®ed fatty acid (NEFA), glycerol, insulin, adrenaline and noradrenaline determinations. At each time blood pressure and heart rate were measured.
Analytical procedures
Oxygen consumption (VO 2 ) and carbon dioxyde production (VCO 2 ) were monitored using an open-circuit ventilated-canopy system (Deltatrac II monitor MBM-100; Datex Instrumentarium Corp., Helsinki). The equipment was calibrated with a reference gas and the accuracy of the system was checked periodically by burning ethanol in the canopy. Energy expenditure was derived from VO 2 and VCO 2 according to indirect calorimetry, 16 neglecting protein oxidation. 17 The results are expressed as the mean of 15 min measurements at each indicated time and values are given in kcalamin. Respiratory quotient (RQ) was calculated as the VCO 2 aVO 2 ratio. Heart rate and blood pressure were measured using an automatic Dynamap device. Plasma glycerol was analysed with an ultrasensitive radiometric method. 18 Plasma glucose and NEFAs were determined with a glucose-oxidase technique (Biotrol, Paris, France) and an enzymatic procedure (Wako, Unipath, Dardilly, France), respectively. Plasma insulin concentrations were measured by immunoradiometric assay (Institut Pasteur, Paris, France). For catecholamine determination, blood was collected over lithium heparin containing 10 mM sodium metabisulphite centrifuged for 10 min at 0 C and the plasma was stored at À80
C. Noradrenaline and adrenaline were assayed by HPLC using electrochemical (amperometric) detection (Waters HPLC system) after isolation from the plasma sample by adsorption on activated alumina and elution with perchloric acid. All samples from each individual were analysed at the same time. Figure 1 Plasma noradrenaline concentrations energy expenditure (EE) and respiratory quotient (RQ) versus time before and after glucose load in obese subjects receiving placebo (s) or idazoxan (d) are presented in the upper, medium and lower parts of the ®gure, respectively. The arrow A indicates placebo or idazoxan administration, the arrow B indicates the oral 1000 g glucose load. Data are expressed as means AE s.e.m. The changes of plasma noradrenaline (upper part), when idazoxan was administred, were higher, after glucose load than with placebo (twoway ANOVA, P 0.013). The increase of EE after glucose load (medium part) was not different after idazoxan or placebo administration (P 0.57). The increase of RQ after glucose load was lower after idazoxan administration than after placebo (P 0.001(lower part). *Indicates the points time that signi®-cantly (P`0.05) differ from the basal value (T 30 ).
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Statistical methods
All values are given as mean AE s.e.m. Between treatment analysis was done using univariate ANOVA with repeated measures for cross-over design. ANOVA taking into account patient, group, patient within group, period, treatment and the interaction treatmentÂperiod (carry-over effect) and within-subject factors such as time, treatment, treatmentÂgroup, groupÂtime, was performed, based upon raw values. P`0.05 was considered as being statistically signi®-cant. The treatment effect (placebo vs idazoxan) was considered signi®cant when no signi®cant carry-over effect nor treatmentÂtime interaction occurred. A Dunnett's post hoc test was used to determine which time points were signi®cantly different within treatment, and a Bonferroni's post hoc test was used to assess the difference between treatments.
Results
Resting EE, cardiovascular and biological parameters of the patients were not different before placebo or idazoxan administration whatever the sequence (no carry-over effect). Figure 1 shows the changes in plasma noradrenline concentration over time after oral administration of placebo or idazoxan followed by the oral glucose load. When placebo was administered, after the glucose load, plasma noradrenaline increased above the baseline level (i.e. T 120 min) from T 180 min to the end of the test, with a maximum of 1.5 fold the basal level at T 270 min (one-way ANOVA with time as factor of analysis, P 0.021). After administration of idazoxan, a rapid increase in plasma noradrenaline was observed lasting from 30 min after the glucose load until the end of the test (P 0.002), with the maximum of 2.3 fold the basal level reached at T 180 min. These changes in plasma noradrenaline after glucose load were signi®-cantly higher when idazoxan was administred compared to placebo (two-way ANOVA, P 0.013). Plasma adrenaline concentration remained unchanged during the experimental period whatever the treatment (not shown). The changes in EE after 100 g oral glucose load are presented in Figure 1 . As expected, glucose load induced an increase in EE. After placebo administration, the effect was signi®cant from 30 min after the Figure 2 Plasma insulin, glucose, non-esteri®ed fatty acids (NEFA) and glycerol concentrations time after glucose load in obese subjects receiving placebo (s) or idazoxan (d). The time course of plasma insulin, glycerol and NEFA after glucose load was not different either after idazoxan administration nor placebo. The increase of glycaemia after to glucose load (left lower part) was lower after idazoxan administration than placebo (P 0.026). See Figure 1 for further details.
Glucose-induced sympathetic response in obesity C Thalamas et al glucose load (T 150 min) until the end of the test (oneway ANOVA, P`0.001); the maximal increase (T 180 min) was 8.4 AE 0.9% of the basal EE measured before glucose load (T 120 min). After administration of idazoxan, the time-course of EE was not signi®cantly different compared to placebo (P 0.57); the maximal increase was 10.1AE 2.7% at T 180 min.
As expected, the respiratory quotient (RQ) increased after the glucose load (one-way ANOVA, P`0.001) but the increase of RQ was lower after idazoxan compared to placebo (Figure 1) . Glucose load induced a decrease in plasma NEFA and glycerol concentrations (Figure 2 ; one-way ANOVA, P`0.001). The time course of NEFA or glycerol was not different after placebo or idazoxan administration (P 0.84, and P 0.20, respectively). As expected, plasma glucose and insulin concentrations increased after glucose load whatever the treatment (P`0.001). However, the increase in plasma glucose was signi®cantly lower after idazoxan than with placebo (P 0.026) while the increase in plasma insulin was not signi®cantly different (P 0.63).
Glucose load after placebo induced non signi®cant changes in arterial systolic and diastolic blood pressure and in heart rate ( Figure 3) . The time-course of these cardiovascular parameters was not signi®cantly different after idazoxan administration when compared to placebo (P 0.77).
Discussion
The present study was performed to evaluate if an a 2 -AR antagonist might improve the glucose-induced activation of the SNS and the glucose-induced thermogenesis in obese patients. The main result of this study is an activation of SNS without change of the glucose-induced thermogenesis.
There is abundant evidence that SNS activation contributes to the thermic effect of glucose 7 in humans: carbohydrate administration increases plasma noradrenaline concentrations 6, 19, 20 and noradrenaline release in muscle nerves. 21 It has been reported that obese patients having a long history of overweight as well as patients at the onset of obesity exhibit a decreased glucose-induced thermogenesis. 11, 13, 14 The factors involved in this defect are still under debate. On the one hand, a defective sympathetic response to food intake has been reported in Pima Indians who exhibit a high prevalence of obesity. 22 On the other, it has been claimed that the defect of glucose-induced thermogenesis in obese patients is rather due to insulin resistance 23, 24 than to an alteration of thermogenesis linked to SNS activity. However reduced glucose induced thermogenesis is present at the onset of obesity in women with normal insulin plasma levels, 14 and an improvement of food-induced thermogenesis without full recovery of the defect is observed in reduced-obese subjects. 20 The activity of the SNS is under the direct tonic control of its own neurotransmitter released in physiological conditions. Noradrenaline release is controlled through a negative feedback mechanism operating through presynaptic a 2 -adrenoceptors. 25 In rodent models of obesity, the a 2 adrenoceptor antagonist yohimbine increases energy expenditure, probably through to the activation of brown adipose tissue. 26 Few experiments have been conducted in non-rodent mammals or in humans. It has been shown that acute oral yohimbine increases plasma noradrenaline concentration and O 2 consumption in the dog. 27 Studies from our group have demonstrated that oral yohimbine, activates the SNS and lipid mobilization in obese and non-obese subjects without cardiovascular side-effects. 4 In fasting obese patients, it has been demonstrated that acute oral yohimbine administration does not promote any change in resting EE whereas it potentiates the EE induced by exercise. 3 Yohimbine is a poorly selective a 2 -adrenoceptor antagonist and is rapidly metabolized in humans. 4 Thus the present study was performed using idazoxan, a highly selective a 2 -adrenoceptor antagonist, at a single dose devoid of cardiovascular side effects, 15 Figure 3 Systolic and diastolic blood pressure and heart rate versus time after glucose load in obese subjects receiving placebo (s) or idazoxan (d). The time courses of the three cardiovascular parameters after glucose load were not different after idazoxan administration nor placebo. See Figure 1 for further details.
Glucose-induced sympathetic response in obesity C Thalamas et al in order to increase glucose-induced SNS activation and thus potentiate glucose-induced thermogenesis in obese patients. Our data show that idazoxan signi®-cantly potentiated the plasma noradrenaline response promoted by the glucose load without change in glucose-induced thermogenesis during the time course of the study (Figure 1 ). In addition, idazoxan did not modify the effects of glucose on blood pressure and heart rate ( Figure 3) . One potential limitation of the present report is the absence of control group to demonstrate if the same kind of glucose-induced SNS activation could induce a thermogenic response in lean healthy subjects. If this effect has been observed in lean subjects, it would not be necessarily of clinical relevance in obese subjects. However, the plasma noradrenaline response promoted by feeding was previously found to be of similar magnitude in obese and control subjects. 20 It can be noticed that the obese patients included in this study had an increased thermogenesis after glucose load (about 8% over the baseline) during placebo administration, close to that previously reported in obese patients.
14 Studies from our group demonstrated that activation of sympathetic tone through administration of the a 2 -adrenoceptor antagonist yohimbine was similar in obese and control subjects. 4 Finally, Jung et al 28 observed reduced thermogenesis during noradrenaline infusion in obese subjects compared to lean subjects, the plasma levels of noradrenaline being adjusted in both populations. Our results, based on the use of an a 2 -adrenoceptor antagonist, support the hypothesis that the defect of food-induced thermogenesis observed in obese patients is rather linked to a default of catecholamine thermogenic ef®ciency than to a defect of SNS activation. In our obese subjects, an increase in SNS activity, pharmacologically-induced, did not increase the thermic effect of glucose.
One unexpected result of the present study was the signi®cant improvement of glucose tolerance after idazoxan administration. We used 100 g glucose because it is the reference load to assess glucoseinduced SNS activity. 29 Idazoxan exhibits a molecular structure with an imidazoline moiety. 15 It has been shown that some imidazoline derivatives increase glucose tolerance in animals through an increased insulin secretion, 30 but recently it has been shown that the imidazoline derivative S-22068 can be considered as a potential antihyperglycaemic agent, probably through an extra-pancreatic mechanism of action. 31 In our study, idazoxan, at the dose used, did not modify the insulin response promoted by the glucose load. Such an observation rather suggests extrapancreatic effects than an increased insulin secretion. The relative decrease of RQ after glucose load with idazoxan compared to placebo suggests either an increase of lipid oxidation linked to an increased noradrenaline release, on an increased glucose storage linked to an increased insulin sensitivity, with reduced glucose oxidation.
In conclusion, acute oral administration of idazoxan, a selective a 2 -AR antagonist, increases glucose-induced sympathetic activity but not energy expenditure in obese subjects. Our data do not argue for the development of a 2 -AR antagonist compounds as anti-obesity treatment.
